Altimmune Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Did you know?
Currently operating at a negative 244702.8% profit margin.
Current Price
$2.82
+8.46%GoodMoat Value
$0.00
99.9% overvaluedProfile
Valuation (TTM)
Market Cap$294.00M
P/E-3.34
EV—
P/B1.31
Shares Out104.25M
P/Sales8166.58
Revenue$36000.00
EV/EBITDA—
Altimmune Inc (ALT) Stock News
ALT Stock News & Headlines
Latest stock news and headlines for Altimmune Inc (ALT). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $2.82. Market cap: $294.00M. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to ALT from financial news sources, helping investors stay current on events that may impact Altimmune Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Altimmune Inc (ALT).